EU Approves Sanofi’s MenQuadfi for Infants as Young as 6 Weeks, Expanding Protection Against a Leading Cause of Acquired Deafness
The vaccine offers protection against invasive meningococcal disease—a bacterial infection known to cause permanent hearing loss in survivors.